48
Participants
Start Date
June 24, 2021
Primary Completion Date
September 2, 2021
Study Completion Date
September 2, 2021
"Treatment A: M207 3.8 mg MiniMac"
"Treatment A: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MiniMac coater and packaged in foil cups"
"Treatment B: M207 3.8 mg MACAP"
"Treatment B: M207 3.8 mg administered as two 1.9 mg patches 30 minutes wear time (upper arm application) - made on a MACAP coater and packaged in foil cups"
Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0
Worldwide Clinical Trials, San Antonio
Zosano Pharma Corporation
INDUSTRY